Barry A. Chestnut

Array ( [id] => 19897851 [patent_doc_number] => 12275757 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use [patent_app_type] => utility [patent_app_number] => 18/337881 [patent_app_country] => US [patent_app_date] => 2023-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 23 [patent_no_of_words] => 10785 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18337881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127625 [patent_doc_number] => 20240132978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => SEQUENCING MICROBIAL CELL-FREE NUCLEIC ACIDS TO DETECT INFLAMMATION, SECONDARY INFECTION, AND DISEASE SEVERITY [patent_app_type] => utility [patent_app_number] => 18/338128 [patent_app_country] => US [patent_app_date] => 2023-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18338128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667778 [patent_doc_number] => 12180511 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Automated production of viral vectors [patent_app_type] => utility [patent_app_number] => 18/337734 [patent_app_country] => US [patent_app_date] => 2023-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 9443 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18337734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127625 [patent_doc_number] => 20240132978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => SEQUENCING MICROBIAL CELL-FREE NUCLEIC ACIDS TO DETECT INFLAMMATION, SECONDARY INFECTION, AND DISEASE SEVERITY [patent_app_type] => utility [patent_app_number] => 18/338128 [patent_app_country] => US [patent_app_date] => 2023-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18338128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19490575 [patent_doc_number] => 12109260 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-08 [patent_title] => Zika vaccines and immunogenic compositions, and methods of using the same [patent_app_type] => utility [patent_app_number] => 18/336439 [patent_app_country] => US [patent_app_date] => 2023-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 31 [patent_no_of_words] => 48320 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18336439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19472610 [patent_doc_number] => 12102673 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => Zika virus vaccine [patent_app_type] => utility [patent_app_number] => 18/334497 [patent_app_country] => US [patent_app_date] => 2023-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 24 [patent_no_of_words] => 22650 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18334497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19218284 [patent_doc_number] => 20240182988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => NUCLEIC ACID DETECTION USING TYPE III CRISPR COMPLEX [patent_app_type] => utility [patent_app_number] => 18/331811 [patent_app_country] => US [patent_app_date] => 2023-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18331811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902986 [patent_doc_number] => 20240018471 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => ENGINEERED RED BLOOD CELLS HAVING RARE ANTIGEN PHENOTYPES [patent_app_type] => utility [patent_app_number] => 18/330167 [patent_app_country] => US [patent_app_date] => 2023-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18330167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19121035 [patent_doc_number] => 11965005 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => Multi-epitope vaccine for the treatment of Alzheimer's disease [patent_app_type] => utility [patent_app_number] => 18/328557 [patent_app_country] => US [patent_app_date] => 2023-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 45 [patent_no_of_words] => 27463 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18328557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19076499 [patent_doc_number] => 11945849 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-02 [patent_title] => Multi-epitope vaccine for the treatment of Alzheimer's disease [patent_app_type] => utility [patent_app_number] => 18/328528 [patent_app_country] => US [patent_app_date] => 2023-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 45 [patent_no_of_words] => 24266 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18328528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877548 [patent_doc_number] => 20240000917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => INFLUENZA VACCINE [patent_app_type] => utility [patent_app_number] => 18/322831 [patent_app_country] => US [patent_app_date] => 2023-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35515 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18322831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922968 [patent_doc_number] => 20240025972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH SARS-COV-2 [patent_app_type] => utility [patent_app_number] => 18/321396 [patent_app_country] => US [patent_app_date] => 2023-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34067 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18321396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877544 [patent_doc_number] => 20240000913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => OIL-BASED ADJUVANTS [patent_app_type] => utility [patent_app_number] => 18/318093 [patent_app_country] => US [patent_app_date] => 2023-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31941 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18318093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806777 [patent_doc_number] => 20230381108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => Method of Safe Administration of Phosphorylated TAU Peptide Vaccine [patent_app_type] => utility [patent_app_number] => 18/316829 [patent_app_country] => US [patent_app_date] => 2023-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18316829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19059002 [patent_doc_number] => 11938196 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Modified viral particles for gene therapy [patent_app_type] => utility [patent_app_number] => 18/316191 [patent_app_country] => US [patent_app_date] => 2023-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 77 [patent_figures_cnt] => 212 [patent_no_of_words] => 32551 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18316191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18994644 [patent_doc_number] => 11911461 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-02-27 [patent_title] => Adjuvanted vaccines containing modified S1 Spike protein of SARS-CoV-2 variant C.1.2 for subcutaneous administration and methods of use [patent_app_type] => utility [patent_app_number] => 18/313017 [patent_app_country] => US [patent_app_date] => 2023-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9567 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18313017 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18772055 [patent_doc_number] => 20230366877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => EBIV NUCLEIC ACID COMPOSITION AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/312072 [patent_app_country] => US [patent_app_date] => 2023-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4409 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 165 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18583952 [patent_doc_number] => 20230266213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => TESTING FOR PARTICULATES [patent_app_type] => utility [patent_app_number] => 18/142624 [patent_app_country] => US [patent_app_date] => 2023-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -81 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18142624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752484 [patent_doc_number] => 20230355738 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => BACTERIOPHAGE-BASED, NEEDLE AND ADJUVANT-FREE, MUCOSAL COVID-19 VACCINE [patent_app_type] => utility [patent_app_number] => 18/138183 [patent_app_country] => US [patent_app_date] => 2023-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19580 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18138183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953669 [patent_doc_number] => 20240041996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/130166 [patent_app_country] => US [patent_app_date] => 2023-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5462 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18130166 [rel_patent_id] =>[rel_patent_doc_number] =>)